[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-respiratory-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-respiratory-diseases":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,60,83,108,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100643314","reference-equations-and-normative-data-for-isometric-quadriceps-and-handgrip-muscles-strength-in-southern-european-populations---restart-a-multicentre-study-100643314",false,"NCT07628530","Reference Equations and Normative Data for Isometric Quadriceps and Handgrip Muscles STrength in Southern European Populations - RESTart: a Multicentre Study","RESTart","Healthy adults cohort\n\nInclusion Criteria:\n\n* Age between 18-89 years.\n* Spanish, Portuguese or Italian, or permanently resident in one of those countries for at least five years.\n* Be community-dwelling (i.e., not hospitalised or institutionalised).\n* Be functionally independent and capable of performing study assessments without assistance or limiting pain.\n* Be able to follow verbal instructions in the local language (Spanish, Portuguese or Italian, as appropriate).\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* Acute or chronic musculoskeletal conditions affecting strength: recent fractures, severe osteoarthrosis, ligament injury, acute tendinitis in hands\u002Fknee areas, among others.\n* Recent surgery (e.g., within the past six months) in upper or lower limbs.\n* Neuromuscular disorders: Parkinson, multiple sclerosis, stroke, peripheral neuropathies, among others.\n* Non-communicable diseases affecting strength or functional status: active cancer, any unstable heart diseases; any CRD; active rheumatological diseases, obesity (BMI≥30kg\u002Fm2), uncontrolled metabolic diseases, among others (not included: controlled dyslipidaemia or arterial hypertension).\n* Cognitive impairments (e.g., dementia) or psychiatric disorders impairing following instructions.\n* Aid devices for walking or compromised functional mobility.\n* Moderate-to-severe pain during the assessment (VAS ≥4).\n* Systemic corticosteroids use for over one week in the previous six months (i.e., risk of muscle atrophy in type II fibres; or steroid myopathy).\n* Muscle relaxants use during the previous week (i.e., risk of not full muscle activation).\n* Pregnancy and postpartum (i.e., potential physiological changes which may alter muscle strength).\n* Current smoking.\n\nChronic respiratory disease cohort\n\nInclusion criteria:\n\n* Aged 18-89 years.\n* Clinical diagnosis of a chronic respiratory disease (e.g., COPD, interstitial lung disease, asthma, bronchiectasis, cystic fibrosis), confirmed by spirometry or clinical records.\n* Clinically stable (no exacerbation within the past four weeks).\n* Capacity to provide informed consent and complete study procedures.\n\nExclusion criteria:\n\n* Coexisting conditions which meet the exclusion criteria defined for healthy participants, apart from chronic respiratory diseases.\n* Current requirement for hospitalisation or acute medical management.\n* Severe functional limitation preventing completion of assessments.",true,"ALL","18 Years","89 Years",{"count":21,"type":22},2815,"ESTIMATED","OBSERVATIONAL","This observational study aims to learn about peripheral muscle strength in healthy adults and people with chronic respiratory diseases. The study aims to develop reference data for quadriceps muscle strength and handgrip in adults living in Southern Europe and to assess whether these reference data can be used in people with chronic respiratory diseases.\n\nThe main questions it aims to answer are:\n\n* What are the normal values for quadriceps and handgrip muscle strength in healthy adults aged 18-89 years living in Spain, Portugal and Italy?\n* Can the reference values developed in healthy adults be applied to people with chronic respiratory diseases?\n\nParticipants will attend one study visit. During this visit, researchers will:\n\n* Measure quadriceps muscle strength and handgrip.\n* Collect information about age, sex, height, weight and other health characteristics.\n* Perform simple functional tests related to mobility and physical performance.\n* Ask participants to complete questionnaires about symptoms, physical activity and health-related quality of life.",[26,27,28],"Muscle Strength","Healthy","Chronic Respiratory Diseases",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"Quadriceps strength","Handgrip","Muscle strength","Reference equations","Reference values","Normative data","Dynamometrry","Healthy adults","Peripheral muscle dysfunction","Chronic respiratory diseases","COPD","Asthma","Bronchiectasis","Interstitial lung disease","Cystic fibrosis","Pulmonary rehabilitation","Southern Europe","NOT_YET_RECRUITING","2026-06-04",{"date":50,"type":51},"2026-06-08","ACTUAL",{"date":53,"type":22},"2026-06",{"date":55,"type":22},"2030-06",{"name":57,"class":58},"University of Alcala","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":16,"sex":17,"minAge":66,"maxAge":4,"enrollmentInfo":67,"targetDuration":69,"studyType":23,"phases":4,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100643772","a-study-to-evaluate-the-diagnostic-performance-of-portable-oscillometry-across-chronic-respiratory-diseases-100643772","NCT07631507","A Study to Evaluate the Diagnostic Performance of Portable Oscillometry Across Chronic Respiratory Diseases","Inclusion Criteria:\n\n* COPD group:\n\n  * Age：≥40\n  * Suspected COPD：COPD-SQ≥16，and no evidence of airflow limitation after bronchodilators\n  * Confirmed COPD：According to the diagnostic criteria in the 2021 Revised Edition of the Chinese Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease and the 2026 GOLD Report, a diagnosis requires the presence of symptoms (such as dyspnea, chronic cough, or sputum production), a history of exposure to risk factors (e.g., smoking, biomass fuels, occupational exposures, or air pollution), evidence of persistent airflow limitation (post-bronchodilator FEV1\u002FFVC \\\u003C 0.70), and the exclusion of alternative diagnoses.\n  * Exclude acute exacerbation within the last month Asthma group：\n  * Age：≥3\n  * Suspected asthma：Patients with chronic respiratory symptoms but no evidence of variable airflow limitation\n  * Confirmed asthma：According to the diagnostic criteria in the 2024 Chinese Guidelines for the Prevention and Treatment of Bronchial Asthma and the 2025 GINA Report, diagnosis requires the presence of recurrent symptoms (such as wheezing, shortness of breath, chest tightness, and cough) that resolve spontaneously or with treatment; evidence of variable airflow limitation (e.g., a positive bronchodilator reversibility test, a positive bronchial provocation test, or an average daily diurnal PEF variability of \\>10% over at least 7 consecutive days); and the exclusion of alternative diagnoses.\n\nHealthy subjects:\n\n* Age ≥ 3 (See Table 1 for details)\n* No respiratory symptoms（cough, expectoration, shortness of breath, wheezing, etc）\n* No history of serious cardiopulmonary or other systemic diseases, especially no history of respiratory diseases and surgery\n* No history of respiratory infection within the past 4 weeks; non-smoker or total lifetime smoking \\\u003C 100 cigarettes\n* No history of occupational exposure to harmful gases or dust, or serious pollution of the work or living environment\n* No abnormalities on chest physical examination\n* No abnormalities were found on chest imaging (X-ray, CT) records within the past year.\n* Body mass index within the normal range (18.5\\~24.9) Confirmed Bronchiectasis Group：\n* Age ≥ 3 years\n* Clinical history consistent with bronchiectasis, confirmed by CT scan\n* No other concurrent or accompanying respiratory diseases at present Confirmed ILD Group：\n* Age ≥ 3 years\n* Fibrotic interstitial lung disease: HRCT scan shows fibrotic lung disease, defined as reticular abnormalities and traction bronchiectasis with or without honeycombing, and the disease extent \\> 10%; or lung tissue biopsy indicates fibrotic interstitial changes\n* No other concurrent or accompanying respiratory diseases at present Confirmed Upper Airway Obstruction Group：\n* Age ≥ 3 years, gender not restricted\n* History of upper airway inflammation, injury, endotracheal intubation or tracheotomy, burns, foreign body aspiration, tracheal tumor, or other conditions that can cause large airway obstruction\n* Clinical manifestations are mainly dyspnea and shortness of breath, which are significantly aggravated after activity, and sometimes symptom exacerbation is related to body position\n* Pulmonary function test shows significant limitation of inspiratory or expiratory flow in the F-V curve, presenting a characteristic plateau pattern\n* At least one of the following evidences: chest CT scan or upper airway three-dimensional reconstruction confirms upper airway stenosis; laryngoscopy or bronchoscopy reveals tracheal\u002Fbronchial wall thickening and\u002For stenosis, intratracheal nodules or neoplasms, tumor infiltration, tracheal mucosal congestion, tracheal cartilage collapse, etc\n\nExclusion Criteria:\n\n* • Contraindications for oscillometry testing and spirometry testing: Oscillometry testing: Severe and intolerable dyspnea, acute exacerbation of respiratory infection, uncontrolled epilepsy, oral or facial diseases or deformities preventing proper latching, tympanic membrane perforation, need for continuous oxygen therapy, indwelling gastric tube, tracheotomy with inability to close the tube, currently undergoing artificial ventilation and unable to temporarily stop the procedure; Spirometry testing: Recent severe cardiovascular disease, epileptic seizures, uncontrolled hypertension, aortic aneurysm, severe hyperthyroidism, heart rate \\>120 bpm, tympanic membrane perforation, other respiratory infectious diseases, etc.;\n\n  * Other respiratory diseases that affect lung function results： such as lung cancer, pneumonia, active pulmonary tuberculosis, pulmonary embolism, etc.; Recent surgical history that affects lung function results, including open-chest surgery, pleural effusion surgery, etc.;\n  * Poor cooperation during basic lung function tests, failing to meet quality control requirements;\n  * Breastfeeding women;\n  * Participants deemed unlikely by the researcher to comply with research procedures and restrictions.","3 Years",{"count":68,"type":22},4000,"1 Day","This is a prospective, multicenter, observational cohort study enrolling approximately 4,000 subjects across about 50 centers, including patients with COPD (confirmed and suspected), asthma (confirmed and suspected), bronchiectasis, interstitial lung disease (ILD), upper airway obstruction (UAO), and healthy controls. Participants will undergo standardized clinical assessments, cough search, FENO, ETCO2, impulse oscillometry, spirometry, and\u002For bronchodilator test, and\u002For bronchoprovocation test, and\u002For diffusion capacity test at a single baseline visit, with no investigational intervention or treatment assignment. The primary objective is to evaluate the diagnostic performance of portable impulse oscillometry in Chronic respiratory diseases and to develop an artificial intelligence diagnostic model for COPD based on oscillometry. The study duration per subject is limited to the screening\u002Fbaseline visit, with no follow-up visits planned.",[40,72,28,42,73,74],"Asthma (Diagnosis)","Interstitial Lung Disease (ILD)","Upper Airway Obstruction","2026-06-02",{"date":50,"type":51},{"date":78,"type":22},"2026-07-30",{"date":80,"type":22},"2027-08-30",{"name":82,"class":58},"The First Affiliated Hospital of Guangzhou Medical University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100625201","belgian-lung-function-study-100625201","NCT07419555","Belgian Lung Function Study","Belgian Lung Function Study: Personalised Longitudinal Lung Function Analysis as a Marker of Disease Progression","AIRCAST","Inclusion Criteria:\n\n* Above 18 years old\n* Diagnosed with a chronic respiratory disease and followed up in one of the participating Belgian hospitals\n* Performed a complete lung function test (spirometry, body plethysmography and diffusion capacity) at baseline\n* Have at least 3 historical spirometry measurements over a minimal time window of 2 years prior to inclusion\n* Planned routine follow-up within standard clinical care in one of the participating hospitals\n\nExclusion Criteria:\n\n* Patients who have had a lung transplantation\n* Patients not being able to give consent to participate",{"count":68,"type":22},"Currently, it remains unclear how to manage serial lung function measurements in a clinical setting. The investigators aimed to tackle this problem by developing a machine learning (ML) model that can accurately predict population and individual lung function trajectories. These predictions would enable the investigators to identify positive or negative deviations, thereby revealing unexpected disease patterns.\n\nA prospective validation is needed that includes data on mortality, hospitalisations, emergency-room visits and patient-reported outcomes. Within this study, the goal is to validate the ML model with the data collected from this observational study.",[28],[95,96,97],"lung function","trajectory","predictions","RECRUITING","2026-03-25",{"date":101,"type":51},"2026-03-30",{"date":99,"type":51},{"date":104,"type":22},"2029-03-01",{"name":106,"class":58},"KU Leuven",4,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100624313","phase-3-interest-of-cryotherapy-in-reducing-pain-during-radial-arterial-blood-sampling-100624313","NCT07408011","Interest of Cryotherapy in Reducing Pain During Radial Arterial Blood Sampling","HOURRA","Inclusion Criteria:\n\n* Patient with a respiratory condition requiring arterial blood gas sampling via radial puncture\n* Patients able to assess their pain using a numerical rating scale\n* Patients reporting a pain score of 0 on the numerical scale at the wrist prior to sampling\n* Patients with no contraindications or allergies to local anesthetics such as lidocaine\u002Fprilocaine\n* Patients aged 18 years or older\n* Patients affiliated with or benefiting from a social security scheme\n* Patients able to give consent and who have signed an informed consent form\n\nExclusion Criteria:\n\n* Patients reporting a pain score \\>0 on the numerical rating scale before sampling\n* Emergency context requiring immediate arterial blood gas results\n* Patients for whom radial arterial puncture is not feasible\n* Known hypersensitivity to local amide-type anesthetics or any component of the lidocaine\u002Fprilocaine cream\n* Pregnant or breastfeeding women\n* Refusal to participate\n* Patients under legal guardianship or conservatorship",{"count":116,"type":22},258,"INTERVENTIONAL",[119],"PHASE3","Arterial puncture for blood gas analysis is a diagnostic procedure used to assess arterial blood gases and monitor a patient's oxygenation status. It is widely regarded by nursing staff as one of the most painful routine procedures. Despite this, the use of local anesthesia prior to arterial puncture remains uncommon in clinical practice.\n\nSeveral types of anesthetic agents and administration techniques have been evaluated, with mixed results regarding their effectiveness in reducing patient-reported pain. Studies comparing subcutaneous lidocaine injection or ethyl chloride spray to no analgesic intervention have shown that ethyl chloride does not significantly reduce pain. Moreover, the discomfort caused by lidocaine injection appears to be comparable to that of the arterial puncture itself, suggesting limited overall benefit from this approach.\n\nOther investigations have similarly reported a lack of significant pain reduction with ethyl chloride spray, although some contradictory findings exist. Ultrasound-guided arterial puncture has been shown to improve success rates and shorten procedure duration; however, it does not appear to influence pain perception.\n\nThe impact of needle size on pain intensity has also been explored, with conflicting results. Some studies found no significant difference in pain when using different gauge needles, while others reported reduced pain with the use of finer needles, such as insulin needles, compared to standard arterial puncture needles.\n\nTopical anesthetic creams combining lidocaine and prilocaine have been assessed in randomized, double-blind trials. These studies found no significant difference between anesthetic and placebo groups in terms of pain intensity or the proportion of painful procedures.\n\nMore recently, cryotherapy has been investigated as a non-pharmacological method to reduce pain prior to arterial puncture. Several randomized controlled trials using varying cryotherapy protocols have generally reported a significant reduction in pain compared to control groups, with longer application times appearing to enhance effectiveness.\n\nHowever, these findings must be interpreted with caution due to methodological limitations. In some studies, sample size calculations were not justified, randomization procedures were poorly described, and reported pain levels were unusually high compared to those typically observed in European populations, raising concerns about external validity. In certain cases, although pain reduction was statistically significant, it did not reach the minimal clinically important difference, limiting its clinical relevance.\n\nConversely, other trials reported very low pain scores following cryotherapy, suggesting a substantial clinical benefit. The short application time required for cryotherapy also makes it far more practical than topical anesthetic creams, which require prolonged application. This practicality supports its use in both emergency and outpatient settings.\n\nSome authors have noted that blinding is challenging when using cryotherapy and have suggested incorporating placebo interventions in future studies to improve methodological rigor.\n\nOverall, systematic analyses indicate that cryotherapy appears to be a safe and potentially effective method for reducing pain during arterial puncture. Nevertheless, the existing evidence is limited by a high risk of bias, underscoring the need for further high-quality randomized controlled trials.\n\nConclusion: Given the promising but methodologically constrained evidence, there is a strong justification for conducting a rigorously designed, placebo-controlled randomized trial to accurately assess the effectiveness of cryotherapy in reducing pain associated with radial arterial puncture.",[28],[123,124,125],"Arterial blood gas","Pain","Cryotherapy","2026-02-10",{"date":128,"type":51},"2026-02-12",{"date":130,"type":22},"2026-02-01",{"date":132,"type":22},"2029-11-01",{"name":134,"class":58},"University Hospital, Brest",2,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":146,"conditions":147,"keywords":152,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":59},"100589343","epigenetics-and-ncd-prevention-in-kazakhstan-personalized-approaches-and-biological-age-prediction-100589343","NCT06953180","Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction","Epigenetics and Prevention of Non-communicable Diseases in Kazakhstan: a Personalized Approach and Biological Age Prediction","Inclusion Criteria:\n\n* Adults aged 18 to 69 years.\n* Residents of 17 regions of Kazakhstan.\n* Willingness to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Age less than 18 years old or over 69 years old.\n* Failure to provide informed consent or incomplete participation in data collection procedures.","69 Years",{"count":145,"type":22},6720,"This study aims to enhance personalized and preventive care for non-communicable diseases (NCDs) in Kazakhstan by examining epigenetic factors, predicting biological age and reproductive function using machine learning, and developing health improvement recommendations.",[148,149,28,150,151],"Cardiovascular Diseases (CVD)","Type 2 Diabetes","Obesity (Disorder)","Chronic Kidney Diseases",[153,154,155,156,157],"DNA methylation","precision medicine","preventive medicine","artificial intelligence","biomedical modeling","2025-07-08",{"date":160,"type":51},"2025-07-11",{"date":162,"type":51},"2025-03-03",{"date":164,"type":22},"2026-12-31",{"name":166,"class":58},"Asfendiyarov Kazakh National Medical University"]